Close
What would you like to look for?
Site search
Search filters

Ikerian closes Series B Financing with strategic partnership

15 November 2024

Ikerian, a healthcare software platform company that organizes multimodal data at-scale, closes the first tranche of USD 8m Series B Financing to advance its AI platform alongside.

HAYA Therapeutics Announces Collaboration with Eli Lilly

5 September 2024

HAYA Therapeutics SA, a Swiss biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions.

Genedata Joins Danaher Corporation

23 August 2024

Genedata AG (“Genedata”), a leading provider of software solutions for biopharmaceutical research and development, has been acquired by Danaher Corporation (NYSE: DHR) (“Danaher”), a leading global innovator in life sciences and diagnostics.

Tybourne Capital Management invests in SkyCell Series D Financing

25 July 2024

Tybourne Capital Management, a global, growth-oriented, fundamental equity investor in public and private markets, recently participated in SkyCell AG's USD 116m Series D financing round.

Memo Therapeutics AG Increases Series C Financing to CHF 45m

15 May 2024

Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised CHF 20m as part of an extension of its series C financing round.

EraCal Therapeutics AG to license certain assets to Novo Nordisk

31 January 2024

EraCal Therapeutics AG ("EraCal"), a Swiss biotech start-up company focusing on the fight of obesity has licensed certain assets to Novo Nordisk for a total amount of EUR 235m in a collaboration and license deal.

GlycoEra AG increases its Series A Financing Round with investment by BMS

22 January 2024

GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional investment by Bristol Meyer Squibb (BMS).

Lallemand subsidiary Danstar Ferment AG takes over Evolva AG

4 January 2024

On 28 December 2023, Danstar Ferment AG, a Swiss subsidiary of Canadian multi-national, Lallemand Inc., has successfully completed the acquisition of Swiss based Evolva AG, subsidiary of SIX listed Evolva Holding SA.

Combination of Proteomedix and Blue Water Biotech to form Onconetix

20 December 2023

Proteomedix AG, ein privates Schweizer Diagnostikunternehmen im kommerziellen Stadium, und Blue Water Biotech, Inc.

Sale of T3 Pharmaceuticals AG to Boehringer Ingelheim

23 November 2023

T3 Pharmaceuticals AG, a biotechnology company with its headquarter in Allschwil, Switzerland has been acquired by Boehringer Ingelheim, a leading family-owned, research-driven biopharmaceutical company based in Ingelheim, Germany...